Brought to you by 
Colby gets exclusive rights to MannKind's cancer immunotherapy program
09 Nov 2021
Executive Summary
Colby Pharmaceutical Co. (signal transduction modulators and immune modulators for various diseases) has licensed exclusive worldwide rights to develop and sell diabetes and cancer firm MannKind Corp.’s disease-specific antigen compounds and associated intra-lymph node injection (ILNI) delivery technologies from the company’s MKC1106 immunotherapy program, including lead candidate MKC1106MT.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Site Specific
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Colby gets exclusive rights to MannKind's cancer immunotherapy program
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice